|
|
Article: AstraZeneca's SEROQUEL(R) Manages Depressive Symptoms and Minimizes Side Effects Common In Other Treatments.
- Article from:
- PR Newswire
- Article date:
- December 13, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ACAPULCO, Mexico, Dec. 13 /PRNewswire/ -- Further evidence of the efficacy of the atypical antipsychotic SEROQUEL(R) (quetiapine fumarate) was presented this week at a major U.S. psychiatric conference. Studies show that SEROQUEL effectively controls the devastating depressive symptoms of psychosis with few of the side effects common with other antipsychotics that often interfere with treatment.
"The data presented today support the use of SEROQUEL as a first-line treatment for psychotic disorders," said Jamie Mullen, M.D., Medical Director, CNS Therapeutic Area, AstraZeneca (NYSE: AZN). "Patients treated with SEROQUEL experienced little weight gain and less ...